Latest Quarterly Report
Filed: 2026-03-09
Key Insights
- The company has been actively conducting research and development, as evidenced by the increases in R&D expenses over the comparable periods.
- Anixa Biosciences has been raising additional capital through an at-the-market equity offering, which could provide funding for its ongoing operations and development efforts.
- The company has granted stock options and other equity-based awards to its employees and consultants as part of its equity compensation plans, which may dilute existing shareholders.